Abstract 65P
Background
Neonatal Nav1.5 (nNav1.5) is a potent tumour metastatic marker found re-expressed in human breast cancer cells with aggressive phenotype and breast tumour tissue positive for lymph node metastasis. Mouse anti-nNav1.5 monoclonal antibody, 4H8 was recently obtained.Neonatal Nav1.5 (nNav1.5) is a potent tumour metastatic marker found re-expressed in human breast cancer cells with aggressive phenotype and breast tumour tissue positive for lymph node metastasis. Mouse anti-nNav1.5 monoclonal antibody, 4H8 was recently obtained. This study aimed to assess the specificity of the 4H8 against nNav1.5.
Methods
4H8 was used as primary antibody in Western blot and immunocytochemistry tested on cells and cell lysates, respectively of two human breast cancer cell line; MDA-MB-231+nNav1.5 and MCF-7-nNav1.5, a mouse mammary cancer cell line, 4T1+nNav1.5, a non-cancerous human breast epithelial, MCF-10A-nNav1.5 and tumour tissue lysate from an orthotopic syngeneic mouse model (4T1+nNav1.5/BALB/c).
Results
were consistent with nNav1.5 protein being more abundantly expressed in aggressive human breast cancer cell line, MDA-MB-231+nNav1.5 and mouse mammary cancer cell line, 4T1+nNav1.5 and tumour tissue lysate from an orthotopic syngeneic mouse model (4T1+nNav1.5/BALB/c) as compared to MCF-7-nNav1.5 and MCF-10A-nNav1.5.
Conclusions
The new antibody described in this work can be a novel tool in studying nNav1.5 expression in breast cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institute of Research for Molecular Medicine.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
78P - Novel allogeneic cell immunotherapy for advanced cancers
Presenter: Ratnavelu Kananathan
Session: e-Poster Display Session
86P - The impact of sarcopenia on chemotherapy toxicity and survival rate among colorectal cancer patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Timotius Hariyanto
Session: e-Poster Display Session
87P - Predictive risk factors and online nomograms for colon cancer with synchronous liver metastasis
Presenter: Yajuan Zhu
Session: e-Poster Display Session
88P - Research of radiomics based on indeterminate lung nodules predicting prognosis of LARC patients
Presenter: Zhang Zhiyuan
Session: e-Poster Display Session
89P - Biomarker analysis of regorafenib dose escalation study (RECC study): A phase II multicenter clinical trial in Japan
Presenter: Masanobu Enomoto
Session: e-Poster Display Session
90P - The role of miR-133a-3p/SP1/IGF1R axis in the progression of colorectal cancer
Presenter: Hui Li
Session: e-Poster Display Session
91P - Prognostic biomarker of clinical outcome in locally advanced rectal cancer in Chinese patients
Presenter: Sandy Ho
Session: e-Poster Display Session
92P - Development and validation of risk and prognostic nomograms for bone metastases in advanced colorectal cancer patients
Presenter: Nan Wang
Session: e-Poster Display Session
93P - Assessment of nutritional status of colorectal cancer patients in a tertiary government hospital
Presenter: Rogelio Velasco
Session: e-Poster Display Session
94P - Prognostic influence of mean platelet volume on stage III rectal cancer patients: A tertiary cancer center study
Presenter: Pavan Jonnada
Session: e-Poster Display Session